Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful faithfully but unsuccessfully to produce an one-time therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV happen to be closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of the past several shares of mine. The first CytoDyn article of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire employment interview which I came away with an inadequate viewpoint of the company.

Irony of irony, my bad viewpoint of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the technology as well as linked intellectual property from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 huge number of) and also the very first new drug application approval ($five million), as well as royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and numerous indications, it has this individual remedy and a “broad pipeline of indications” since it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active company with diverse interests albeit focused on leronlimab, several illness types, multiple presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself through the really beginning of my interest in this business. Judging by way of the multiples of a huge number of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *